AzurRx BioPharma, Inc.
AZRXNASDAQHealthcare
$3.45
+$0.07(+2.07%)
Market Cap$3432760
P/E Ratio—
52W High$3.66
52W Low$3.38
AzurRx BioPharma, Inc. (AZRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AZRX · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2021Report Date: Aug 16, 2021EPS Actual
-$1.60
Est. -$0.72 · -122.2%
Revenue
—
Fiscal Period
Q3 FY2021
FY ends December
Report Date
Aug 16, 2021
After Market Close
▼ Miss EPS
AZRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q3 FY2021 | Aug 16, 2021 | -$0.72 | -$1.60 | -122.2% | — | — | — |
| ▼ Q2 FY2021 | May 24, 2021 | -$0.72 | -$1.40 | -94.4% | — | — | — |
| ▼ Q1 FY2021 | Mar 31, 2021 | -$1.36 | -$3.10 | -127.9% | — | — | — |
| ▼ Q4 FY2020 | Nov 16, 2020 | -$1.36 | -$4.70 | -245.6% | — | — | — |
| ▼ Q3 FY2020 | Aug 14, 2020 | -$1.06 | -$1.70 | -60.4% | — | — | — |
| ▼ Q2 FY2020 | May 15, 2020 | -$1.17 | -$2.00 | -70.9% | — | — | — |
| ▲ Q1 FY2020 | Mar 30, 2020 | -$1.60 | -$0.48 | +70.0% | — | — | — |
| ▼ Q4 FY2019 | Nov 14, 2019 | -$1.57 | -$1.70 | -8.3% | — | — | — |
Q3 FY2021
Aug 16, 2021Miss
EPS Actual
-$1.60
EPS Est.
-$0.72
EPS Surpr.
-122.2%
Revenue
—
Q2 FY2021
May 24, 2021Miss
EPS Actual
-$1.40
EPS Est.
-$0.72
EPS Surpr.
-94.4%
Revenue
—
Q1 FY2021
Mar 31, 2021Miss
EPS Actual
-$3.10
EPS Est.
-$1.36
EPS Surpr.
-127.9%
Revenue
—
Q4 FY2020
Nov 16, 2020Miss
EPS Actual
-$4.70
EPS Est.
-$1.36
EPS Surpr.
-245.6%
Revenue
—
Q3 FY2020
Aug 14, 2020Miss
EPS Actual
-$1.70
EPS Est.
-$1.06
EPS Surpr.
-60.4%
Revenue
—
Q2 FY2020
May 15, 2020Miss
EPS Actual
-$2.00
EPS Est.
-$1.17
EPS Surpr.
-70.9%
Revenue
—
Q1 FY2020
Mar 30, 2020Beat
EPS Actual
-$0.48
EPS Est.
-$1.60
EPS Surpr.
+70.0%
Revenue
—
Q4 FY2019
Nov 14, 2019Miss
EPS Actual
-$1.70
EPS Est.
-$1.57
EPS Surpr.
-8.3%
Revenue
—
No analyst estimates available for AZRX.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2021 | Aug 16, 2021 | -122.2% | $5.90 | $5.55 | -5.93% |
| ▼ Q2 FY2021 | May 24, 2021 | -94.4% | $8.90 | $8.24 | -7.42% |
| ▼ Q1 FY2021 | Mar 31, 2021 | -127.9% | $13.00 | $13.40 | +3.08% |
| ▼ Q4 FY2020 | Nov 16, 2020 | -245.6% | $7.30 | $7.01 | -3.97% |
| ▼ Q3 FY2020 | Aug 14, 2020 | -60.4% | $9.90 | $9.30 | -6.06% |
| ▼ Q2 FY2020 | May 15, 2020 | -70.9% | $8.12 | $8.19 | +0.86% |
| ▲ Q1 FY2020 | Mar 30, 2020 | +70.0% | $5.68 | $5.71 | +0.53% |
| ▼ Q4 FY2019 | Nov 14, 2019 | -8.3% | $6.10 | $7.75 | +27.05% |
Q3 FY2021-5.93%
Report Date
Aug 16, 2021
EPS Beat/Miss
-122.2%
Price Before
$5.90
Price After
$5.55
Q2 FY2021-7.42%
Report Date
May 24, 2021
EPS Beat/Miss
-94.4%
Price Before
$8.90
Price After
$8.24
Q1 FY2021+3.08%
Report Date
Mar 31, 2021
EPS Beat/Miss
-127.9%
Price Before
$13.00
Price After
$13.40
Q4 FY2020-3.97%
Report Date
Nov 16, 2020
EPS Beat/Miss
-245.6%
Price Before
$7.30
Price After
$7.01
Q3 FY2020-6.06%
Report Date
Aug 14, 2020
EPS Beat/Miss
-60.4%
Price Before
$9.90
Price After
$9.30
Q2 FY2020+0.86%
Report Date
May 15, 2020
EPS Beat/Miss
-70.9%
Price Before
$8.12
Price After
$8.19
Q1 FY2020+0.53%
Report Date
Mar 30, 2020
EPS Beat/Miss
+70.0%
Price Before
$5.68
Price After
$5.71
Q4 FY2019+27.05%
Report Date
Nov 14, 2019
EPS Beat/Miss
-8.3%
Price Before
$6.10
Price After
$7.75
Avg Beat Reaction+0.53%
Avg Miss Reaction+1.09%
Beat Rate1 / 8 quarters
Largest Move+27.05% (Q4 FY2019)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AZRX ends December
AzurRx BioPharma, Inc. (AZRX) most recently reported earnings on August 16, 2021 for Q3 FY2021, posting EPS of $-1.60 — missing the analyst consensus of $-0.72 by -122.2%. The next AZRX earnings date is expected around September 1, 2026.
Each quarter, investors track AZRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AZRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AZRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AZRX earnings · 5 questionsAzurRx BioPharma, Inc.'s next earnings report is expected around September 1, 2026. AZRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AZRX historically reports after market close (AMC).
AZRX earnings datewhen is AZRX earningsAZRX next earnings datewhen does AZRX report earningsAZRX earnings calendar
▸ Source: FMP · AzurRx BioPharma, Inc. SEC filings · US GAAP · AzurRx BioPharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026